Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

May 20, 2011

 

 

AMGEN INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-12477   95-3540776

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

One Amgen Center Drive

Thousand Oaks, California

  91320-1799
(Address of principal executive offices)   (Zip Code)

805-447-1000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting of Stockholders on May 20, 2011. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows:

Item 1 - Election of Directors

Each of the following 12 nominees for director were elected to serve a one-year term expiring at the Company’s 2012 Annual Meeting of Stockholders.

 

Name

  Votes For     Votes Against     Abstain     Broker Non-Votes  

Dr. David Baltimore

    582,828,712        121,546,553        3,963,576        97,107,133   

Mr. Frank J. Biondi, Jr.

    616,742,168        86,752,259        4,844,414        97,107,133   

Mr. François de Carbonnel

    581,543,546        121,832,088        4,963,207        97,107,133   

Dr. Vance D. Coffman

    582,141,277        121,267,372        4,930,192        97,107,133   

Dr. Rebecca M. Henderson

    582,216,541        121,241,068        4,881,232        97,107,133   

Mr. Frank C. Herringer

    566,697,965        136,724,853        4,916,023        97,107,133   

Dr. Gilbert S. Omenn

    675,969,133        28,390,527        3,979,181        97,107,133   

Ms. Judith C. Pelham

    675,256,425        28,343,007        4,739,409        97,107,133   

Admiral J. Paul Reason, USN (Retired)

    656,275,294        47,900,173        4,163,374        97,107,133   

Mr. Leonard D. Schaeffer

    657,737,153        46,437,617        4,164,071        97,107,133   

Mr. Kevin W. Sharer

    657,823,118        46,878,730        3,636,993        97,107,133   

Dr. Ronald D. Sugar

    622,544,828        81,549,176        4,244,837        97,107,133   

Item 2 - Ratification of Selection of Independent Registered Public Accountants

Ernst & Young LLP was ratified as the Company’s independent registered public accountants for the fiscal year ending December 31, 2011. No Broker Non-Votes resulted from the vote on this proposal.

 

For:

 

793,657,902

 

Against:

 

8,368,199

 

Abstain:

 

3,419,873

 

Item 3 - Advisory Vote on Executive Compensation

The advisory vote on executive compensation was approved.

 

For:

 

393,700,304

 

Against:

 

309,162,287

 

Abstain:

 

5,476,250

 

Broker Non-Votes:

 

97,107,133

 

 

2


Item 4 - Advisory Vote on Frequency of Future Stockholder Advisory Votes on Executive Compensation

One year was selected for the advisory vote on the frequency of future stockholder advisory votes on executive compensation.

 

One year:

 

629,413,248

 

Two years:

 

3,456,971

 

Three years:

 

71,428,963

 

Abstain:

 

4,039,660

 

Broker Non-Votes:

 

97,107,133

 

Item 5 - Stockholder Proposal

Stockholder Proposal #1

The stockholder proposal relating to shareholder action by written consent was approved.

 

For:

 

355,515,202

 

Against:

 

345,480,290

 

Abstain:

 

7,343,349

 

Broker Non-Votes:

 

97,107,133

 

The above voting results represent 50.19% approval under the required voting standard (based on votes present or represented by proxy and entitled to vote) or 50.19% approval of the votes cast and 38.10% approval of the outstanding shares.

No other matters were submitted for stockholder action.

A copy of the press release announcing the vote results is furnished as Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release, dated May 20, 2011

 

3


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AMGEN INC.
Date: May 20, 2011    
  By:  

/s/ David J. Scott

  Name:   David J. Scott
  Title:   Senior Vice President, General Counsel and Secretary


EXHIBIT INDEX

 

Exhibit
No.

  

Document Description

99.1    Press Release, dated May 20, 2011